Heart Failure and Diabetes: A Two-Way Street Influenced by Therapy
A recent analysis explores the complex interplay between heart failure events and new-onset diabetes in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). The research investigates the role of finerenone, a non-steroidal mineralocorticoid receptor antagonist, in this dynamic. Findings suggest that experiencing a heart failure event significantly increases the risk of subsequently developing diabetes. Conversely, the study examines whether finerenone treatment can mitigate this risk, potentially offering a dual cardiorenal protective effect by not only reducing heart failure hospitalizations but also interrupting the pathophysiological cascade leading to new-onset diabetes.
Why it might matter to you: For cardiology professionals, this underscores the importance of proactive diabetes screening following heart failure decompensation, especially in HFmrEF/HFpEF populations. The potential for finerenone to modify disease progression highlights a shift towards therapies that address interconnected cardiometabolic pathways, which could refine risk stratification and long-term management strategies. This evidence may influence clinical trial design and therapeutic guidelines for managing the growing cohort of patients with overlapping heart failure and metabolic syndrome.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
